Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib and Trametinib in BRAF V600E Mutant NSCLC
NCT03543306Phase 2Unknown
- Sponsor
- Asan Medical Center
- Start
- Jun 2018
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dabrafenib + trametinib, trametinib in non-small cell lung cancer (NSCLC), sponsored by Asan Medical Center. Status: unknown.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03543306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03543306.